美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

First Tracks Biotherapeutics Inc

34.68

+2.838.89%

成交量：435.35万

成交额：1.57亿

市值：12.39亿

市盈率：-7.66

高：40.50

开：39.60

低：33.59

收：31.85

52周最高：49.91

52周最低：14.72

股本：3,573.08万

流通股本：3,474.88万

量比：19.77

换手率：12.53%

股息：- -

股息率：- -

每股收益(TTM):-4.5296

净资产收益率：-48.91%

总资产收益率：-28.97%

市净率：7.34

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

First Tracks Biotherapeutics 乳糜泻药物试验传捷报盘前股价飙升13.3%

First Tracks受乳糜泻药物临床试验取得积极结果的提振而股价大涨

First Tracks Biotherapeutics宣布：Anb033用于嗜酸性食管炎的1B期队列顶线数据预计2027年第三季度公布

First Tracks Biotherapeutics公布Anb033在乳糜泻麸质激发试验中取得积极顶线结果

First Tracks Biotherapeutics公司Anb033在乳糜泻1B期试验中取得统计学显著保护效果

First Tracks Biotherapeutics：Anb033 白癜风及另一适应症二期开发拟于2027年上半年启动

First Tracks Biotherapeutics：Anb033第六周Vh:Cd比值安慰剂校正后差异达+0.49（p=0.009）

First Tracks Biotherapeutics将于2026年10月12日公布Anb033（一种Cd122拮抗剂）治疗乳糜泻1B期试验第一队列的主要数据

Canaccord Genuity首次覆盖First Tracks Biotherapeutics，给予买入评级目标价50美元

美国研究综述-爱彼迎、Five Below、Silgan Holdings

美国研究综述-爱彼迎、Five Below、Silgan Holdings

富国银行首次覆盖First Tracks Biotherapeutics，给予“超配”评级及30美元目标价

First Tracks Biotherapeutics公布2026年第一季度财务业绩并更新业务进展

First Tracks Biotherapeutics公司：售股股东或可出售高达10.5股普通股 - SEC文件披露

美国研究综述-Alphabet、高露洁-棕榄、Welltower

Piper Sandler首予First Tracks Biotherapeutics增持评级目标价54美元

H.C. Wainwright首予First Tracks Biotherapeutics买入评级目标价30美元

Leerink Partners首次覆盖First Tracks Biotherapeutics 给予"跑赢大盘"评级及46美元目标价

巴克莱首予First Tracks Biotherapeutics增持评级目标价40美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/TRAX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAX\",,,,,undefined,":{"symbol":"TRAX","market":"US","secType":"STK","nameCN":"First Tracks Biotherapeutics Inc","latestPrice":34.68,"timestamp":1791818225018,"preClose":31.85,"halted":0,"volume":4353476,"delay":0,"changeRate":0.08885400313971736,"floatShares":34748800,"shares":35730843,"eps":-4.529554,"marketStatus":"交易中","change":2.83,"latestTime":"10-12 11:17:06 EDT","open":39.6,"high":40.5,"low":33.59,"amount":157124271.386632,"amplitude":0.216954,"askPrice":34.73,"askSize":1,"bidPrice":34.62,"bidSize":205,"shortable":3,"etf":0,"ttmEps":-4.529554,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":31.85,"preHourTrading":{"tag":"盘前","latestPrice":39.25,"preClose":31.85,"latestTime":"09:29 EDT","volume":687228,"amount":27160710.9195,"timestamp":1791811799999,"change":7.4,"changeRate":0.232339,"amplitude":0.533121},"postHourTrading":{"tag":"盘后","latestPrice":31.85,"preClose":31.85,"latestTime":"19:30 EDT","volume":4446,"amount":141605.1,"timestamp":1791588605869,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":19.769049,"impliedVol":1.0887,"impliedVolPercentile":0.785},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAX\",,,,,undefined,":{"symbol":"TRAX","floatShares":34748800,"roa":"-28.97%","roe":"-48.91%","lyrEps":0,"volumeRatio":19.769049,"shares":35730843,"dividePrice":0,"high":40.5,"amplitude":0.216954,"preClose":31.85,"low":33.59,"week52Low":14.72,"pbRate":"7.34","week52High":49.9114,"institutionHeld":0,"latestPrice":34.68,"committee":0.990291,"eps":-4.529554,"divideRate":0,"volume":4353476,"delay":0,"ttmEps":-4.529554,"open":39.6,"prevYearClose":20,"prevWeekClose":31.85,"prevMonthClose":35.44,"prevQuarterClose":35.44,"fiveDayClose":32.99,"twentyDayClose":37.57,"sixtyDayClose":36.515},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"TRAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1790827200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAX","date":"2026-10-09","current":-7.744692,"percent":0.513043,"low":-10.141689,"twenty":-9.325896,"median":-7.282788,"eighty":-3.662799,"high":-3.156022,"avg":-6.458276,"sd":2.56113,"marketCap":1143744284},"quantilePoints":[{"date":"2026-04-24","current":-3.975194,"twenty":-3.975194,"median":-3.975194,"eighty":-3.975194,"marketCap":660227979},{"date":"2026-05-01","current":-4.868566,"twenty":-4.868566,"median":-4.085034,"eighty":-3.799448,"marketCap":808605530},{"date":"2026-05-08","current":-3.728313,"twenty":-4.68236,"median":-4.236719,"eighty":-3.799448,"marketCap":619224346},{"date":"2026-05-15","current":-3.799448,"twenty":-4.433387,"median":-4.031683,"eighty":-3.799448,"marketCap":631038952},{"date":"2026-05-22","current":-3.452672,"twenty":-4.299486,"median":-3.855938,"eighty":-3.664859,"marketCap":584796305},{"date":"2026-05-29","current":-3.259026,"twenty":-4.249272,"median":-3.799448,"eighty":-3.475745,"marketCap":551997467},{"date":"2026-06-05","current":-3.749322,"twenty":-4.203244,"median":-3.738817,"eighty":-3.411676,"marketCap":635041334},{"date":"2026-06-12","current":-3.508294,"twenty":-4.109513,"median":-3.726221,"eighty":-3.329068,"marketCap":594217248},{"date":"2026-06-18","current":-3.743141,"twenty":-4.020386,"median":-3.683399,"eighty":-3.361617,"marketCap":633994562},{"date":"2026-06-26","current":-3.372329,"twenty":-3.945066,"median":-3.663829,"eighty":-3.37851,"marketCap":571188276},{"date":"2026-07-02","current":-3.829664,"twenty":-3.955109,"median":-3.663829,"eighty":-3.376449,"marketCap":648649362},{"date":"2026-07-10","current":-6.674616,"twenty":-4.112294,"median":-3.726221,"eighty":-3.397462,"marketCap":1130513144},{"date":"2026-07-17","current":-7.459502,"twenty":-4.261943,"median":-3.735727,"eighty":-3.424655,"marketCap":1263453116},{"date":"2026-07-24","current":-7.754091,"twenty":-4.794084,"median":-3.774042,"eighty":-3.434543,"marketCap":1313349220},{"date":"2026-07-31","current":-9.842999,"twenty":-6.999282,"median":-3.799448,"eighty":-3.441135,"marketCap":1667157964},{"date":"2026-08-07","current":-9.334163,"twenty":-7.464446,"median":-3.842801,"eighty":-3.45844,"marketCap":1580973783},{"date":"2026-08-14","current":-9.814035,"twenty":-7.742967,"median":-3.975194,"eighty":-3.486045,"marketCap":1573229017},{"date":"2026-08-21","current":-9.33927,"twenty":-8.651869,"median":-4.081492,"eighty":-3.504998,"marketCap":1497122321},{"date":"2026-08-28","current":-9.97229,"twenty":-9.339073,"median":-4.144854,"eighty":-3.509324,"marketCap":1598597915},{"date":"2026-09-04","current":-9.475235,"twenty":-9.448042,"median":-4.257739,"eighty":-3.516946,"marketCap":1518918135},{"date":"2026-09-11","current":-8.465524,"twenty":-9.33927,"median":-4.366436,"eighty":-3.530954,"marketCap":1357057417},{"date":"2026-09-18","current":-8.737455,"twenty":-9.338283,"median":-4.868566,"eighty":-3.539195,"marketCap":1400649045},{"date":"2026-09-25","current":-7.986302,"twenty":-9.334163,"median":-6.877533,"eighty":-3.588636,"marketCap":1280236104},{"date":"2026-10-02","current":-7.560574,"twenty":-9.330354,"median":-7.443021,"eighty":-3.633958,"marketCap":1211990194},{"date":"2026-10-09","current":-7.134846,"twenty":-9.325896,"median":-7.282788,"eighty":-3.662799,"marketCap":1143744284}],"updateTime":1791817781437},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1148780894","title":"First Tracks Biotherapeutics 乳糜泻药物试验传捷报 盘前股价飙升13.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148780894","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148780894?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 20:16","pubTimestamp":1791807367,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics Inc（TRAX）盘前股价大幅上涨13.3%，此前该公司公布了乳糜泻疾病药物试验的积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674887276","title":"First Tracks受乳糜泻药物临床试验取得积极结果的提振而股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2674887276","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674887276?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:52","pubTimestamp":1791805979,"startTime":"0","endTime":"0","summary":"BUZZ-First Tracks受乳糜泻药物临床试验取得积极结果的提振而股价大涨10月12日-** 生物技术公司 First Tracks Biotherapeutics（TRAX.O）的股价在盘前交易中飙升16.2%，至37美元** 该公司宣布 (link)其用于治疗乳糜泻的药物ANB033在麸质挑战试验中取得了积极的初步结果** ANB033是该公司用于治疗自身免疫性及炎症性疾病（包括乳糜泻","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nL4S45Y0PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182379086","title":"First Tracks Biotherapeutics宣布：Anb033用于嗜酸性食管炎的1B期队列顶线数据预计2027年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1182379086","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182379086?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:03","pubTimestamp":1791803009,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics公司透露，针对Anb033在嗜酸性食管炎适应症上的1B期队列研究，其顶线数据预计将于2027年第三季度出炉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188348882","title":"First Tracks Biotherapeutics公布Anb033在乳糜泻麸质激发试验中取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1188348882","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188348882?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:03","pubTimestamp":1791802999,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics公布Anb033在乳糜泻麸质激发试验中取得积极顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103323680","title":"First Tracks Biotherapeutics公司Anb033在乳糜泻1B期试验中取得统计学显著保护效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103323680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103323680?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:03","pubTimestamp":1791802997,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics公司宣布，其候选药物Anb033在乳糜泻1B期临床试验中展现出统计学显著的保护作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157730978","title":"First Tracks Biotherapeutics：Anb033 白癜风及另一适应症二期开发拟于2027年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1157730978","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157730978?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:01","pubTimestamp":1791802869,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics 宣布，Anb033 针对白癜风及其他一项适应症的二期临床开发项目，预计将于2027年上半年正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171997782","title":"First Tracks Biotherapeutics：Anb033第六周Vh:Cd比值安慰剂校正后差异达+0.49（p=0.009）","url":"https://stock-news.laohu8.com/highlight/detail?id=1171997782","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171997782?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 19:01","pubTimestamp":1791802868,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics公司公布的数据显示，Anb033在第6周时，Vh:Cd比值的安慰剂校正后差异为+0.49，p值为0.009。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162596516","title":"First Tracks Biotherapeutics将于2026年10月12日公布Anb033（一种Cd122拮抗剂）治疗乳糜泻1B期试验第一队列的主要数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1162596516","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162596516?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 04:01","pubTimestamp":1791748867,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics将于2026年10月12日公布Anb033（一种Cd122拮抗剂）治疗乳糜泻1B期试验第一队列的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197049766","title":"Canaccord Genuity首次覆盖First Tracks Biotherapeutics，给予买入评级目标价50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197049766","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197049766?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 20:44","pubTimestamp":1790772254,"startTime":"0","endTime":"0","summary":"Canaccord Genuity首度启动对First Tracks Biotherapeutics Inc的覆盖，授予买入评级，目标价定为50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713954","title":"美国研究综述-爱彼迎、Five Below、Silgan Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713954","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713954?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 14:50","pubTimestamp":1786603808,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、Five Below、Silgan Holdings路透8月13日-周四，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括爱彼迎、Five Below和Silgan Holdings。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4S44A0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","LQDA","OI","BOAT","NURE","KURA","CSCO","ALGM","ANRO","CAH","ELIS","MTSI","OII","PAYX","RHP","ZG","TRAX","LLY","PTCT","PARK","ABNB","CURE","YELP","OZEM","AMRZ","SRRK","LOW","FIVE","FLY","SLGN","SPHR","INO","OSCR","DUOL","UNCY","MSGE","COHR","EAT","INSW","MNPR","FLYT","CYTK","LLII","TRIP","AMTM","ARMK","IBRN","Z","HP","ACM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659139540","title":"美国研究综述-爱彼迎、Five Below、Silgan Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659139540","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659139540?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 14:50","pubTimestamp":1786603808,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、Five Below、Silgan Holdings路透8月13日-周四，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括爱彼迎、Five Below和Silgan Holdings。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4T44A0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHX","OI","SLGN","FIVE","INSW","LLY","ARMK","MSGE","TRAX","IXJ","KURA","Z","TRIP","ZG","AMTM","UNCY","YELP","AMRZ","PAYX","XES","EAT","PTCT","INO","ACM","DUOL","MTSI","FLY","COHR","MNPR","ALGM","HRTS","SPHR","RHP","CYTK","OSCR","ANRO","AGNG","CSCO","PARK","CAH","IHE","ILDR","HP","OII","MNSH","ABNB","TRUH","LQDA","SRRK","LOW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160045773","title":"富国银行首次覆盖First Tracks Biotherapeutics，给予“超配”评级及30美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1160045773","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160045773?lang=zh_cn&edition=fundamental","pubTime":"2026-06-08 18:46","pubTimestamp":1780915574,"startTime":"0","endTime":"0","summary":"富国银行分析师团队启动了对生物制药公司First Tracks Biotherapeutics Inc.的研究覆盖，并给予其股票“超配”评级。该行同时设定了30美元的目标股价，预示着分析师认为该公司股票在当前水平上具有显著的上行潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102003350","title":"First Tracks Biotherapeutics公布2026年第一季度财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1102003350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102003350?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 04:16","pubTimestamp":1778789777,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics Inc. 近日公布了其截至2026年第一季度的财务业绩，并向市场同步更新了公司最新的业务动态。此次发布涵盖了公司在关键研发项目上的推进情况、管线布局的调整以及未来的战略规划，旨在为投资者提供全面的运营视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137960030","title":"First Tracks Biotherapeutics公司：售股股东或可出售高达10.5股普通股 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1137960030","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137960030?lang=zh_cn&edition=fundamental","pubTime":"2026-05-09 04:40","pubTimestamp":1778272801,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的一份文件显示，First Tracks Biotherapeutics Inc的现有售股股东，可能将出售高达10.5股公司普通股。\n这份文件揭示了股东潜在的股份出售计划，相关信息已按监管要求进行备案。具体细节可在相关SEC文件中查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632818936","title":"美国研究综述-Alphabet、高露洁-棕榄、Welltower","url":"https://stock-news.laohu8.com/highlight/detail?id=2632818936","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632818936?lang=zh_cn&edition=fundamental","pubTime":"2026-05-04 15:35","pubTimestamp":1777880141,"startTime":"0","endTime":"0","summary":"美国研究综述-Alphabet、高露洁-棕榄、Welltower路透5月4日 - 周一，华尔街的证券分析师们调整了多家在美国上市公司的评级和目标股价，其中包括Alphabet、高露洁-棕榄和Welltower。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4T41H0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","FTAI","CORZ","ACA","AAPL","DAR","GOOGL","MTZ","KEX","CNC","MSFT","MTCH","BLDR","BOBS","ETSY","WELL","CSGP","META","MLM","AMZY","TRAX","ESS","ESPR","AAPB","AMZZ","AMZN","FICO","AXSM","GDDY","DAVE","AMGN","APLY","SAM","AMZU","EL","AX","FLS","AAPW","CAH","AAPU","CBOE","CHD","DECK","AAPD","AAPY","BTSG","LEA","AMP","HSY","AAPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166118707","title":"Piper Sandler首予First Tracks Biotherapeutics增持评级 目标价54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166118707","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166118707?lang=zh_cn&edition=fundamental","pubTime":"2026-05-04 11:36","pubTimestamp":1777865787,"startTime":"0","endTime":"0","summary":"投行Piper Sandler首次覆盖生物技术公司First Tracks Biotherapeutics，给予\"增持\"评级，并设定54美元的目标股价。\n该评级反映出分析师对该公司研发管线前景的乐观预期。目标价的设定基于对其创新疗法的估值评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137187617","title":"H.C. Wainwright首予First Tracks Biotherapeutics买入评级 目标价30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137187617","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137187617?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 18:13","pubTimestamp":1777371189,"startTime":"0","endTime":"0","summary":"生物制药公司First Tracks Biotherapeutics Inc获得投资机构H.C. Wainwright的首次覆盖，该机构给予其\"买入\"评级，并将目标股价设定为30美元。\n此次覆盖标志着华尔街对这家专注于创新疗法开发的生物技术企业投下信任票。分析师在研报中指出，公司核心研发管线具备显著商业化潜力，其专利技术平台在靶向治疗领域展现出独特优势。\n目标价格的设定反映了机构对公司长期价值增长空间的乐观预期。若股价能达到该目标位，较当前交易水平将存在可观上涨空间。市场关注点将集中于公司后续临床进展及合作伙伴关系拓展等关键催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150338315","title":"Leerink Partners首次覆盖First Tracks Biotherapeutics 给予\"跑赢大盘\"评级及46美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150338315","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150338315?lang=zh_cn&edition=fundamental","pubTime":"2026-04-24 18:10","pubTimestamp":1777025447,"startTime":"0","endTime":"0","summary":"生物制药新锐First Tracks Biotherapeutics Inc迎来资本市场重要里程碑——知名投行Leerink Partners今日发布首份覆盖报告，给予该公司\"跑赢大盘\"的积极评级。这份覆盖报告的发布，标志着专业投资机构对First Tracks Biotherapeutics研发管线与商业前景的正式认可。Leerink Partners作为医疗健康领域的顶尖投行，其评级动向往往引发市场高度关注。随着创新药企融资环境逐步改善，具备差异化技术平台的First Tracks Biotherapeutics有望借助资本市场的东风，加速其前沿疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148679757","title":"巴克莱首予First Tracks Biotherapeutics增持评级 目标价40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148679757","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148679757?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 18:39","pubTimestamp":1776854355,"startTime":"0","endTime":"0","summary":"巴克莱集团宣布首次覆盖生物制药公司First Tracks Biotherapeutics，并给予\"增持\"评级。该机构同时设定了40美元的目标股价，显示出对该公司未来发展潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}